

Can playing Neuro-World mobile games improve cognitive function in people who have had a stroke 2 years or more previously?

Submission date 22/03/2019	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/03/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 08/01/2020	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Rehabilitation games have the potential to enable stroke survivors to repeatedly practice and improve their cognitive function. However, there are no mobile game solutions that are specifically developed for cognitive rehabilitation and clinically tested. The aim of this study is to test Neuro-World, six mobile games developed for cognitive rehabilitation.

Who can participate?

Stroke survivors with mild cognitive function in their chronic stage (1 year or longer since their last onset)

What does the study involve?

Participants are randomly allocated to one of two groups. One group play Neuro-World games for 30 minutes (5 minutes for each game) a day, 2 days a week for 12 weeks in addition to their medical care, while the other group receive only medical care. Participants are assessed before and after the treatment (12 weeks).

What are the possible benefits and risks of participating?

Study subjects may improve their cognitive function by participating in the study. Playing the games may cause eye and mental fatigue.

Where is the study run from?

Heeyeon Rehabilitation Hospital (South Korea)

When is the study starting and how long is it expected to run for?

September 2017 to October 2018

Who is funding the study?

Investigator initiated and funded

Who is the main contact?

Mr Hee-Tae Jung

hjung@cs.umass.edu

Contact information

Type(s)

Public

Contact name

Mr Hee-Tae Jung

ORCID ID

<http://orcid.org/0000-0001-8921-570X>

Contact details

College of Information and Computer Sciences

University of Massachusetts Amherst

Amherst

United States of America

01003

+1 (0)4135452744

hjung@cs.umass.edu

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

2018-4728

Study information

Scientific Title

Effectiveness of self-administered cognitive rehabilitation games in chronic stroke survivors with mild-to-moderate cognitive impairment: a randomized controlled trial

Acronym

Neuro-World Clinical Study

Study objectives

Self-administration of Neuro-World, mobile cognitive rehabilitation games, can improve cognitive function of chronic-stage stroke patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 06/05/2018, University of Massachusetts Amherst Institutional Review Board (Research Compliance Human Research Protection Office (HRPO), 108 Research Administration Building, 70 Butterfield Terrace, Amherst, MA 01003-9242; Tel: +1 (0)413-545-3428; Email: ncswett@ora.umass.edu), Protocol ID: 2018-4728

Study design

Single-center randomized controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Stroke survivors with mild-to-moderate cognitive impairment (18 points or greater in K-MMSE) in their chronic stage (2 years or longer since their last onset)

Interventions

Participants were randomized using a random number generator. An experimental group self-administered 24 30-minute sessions of Neuro-World, six mobile games for cognitive rehabilitation, twice a week for 12 weeks in addition to their medical care while the control group received only medical care.

Intervention Type

Device

Phase

Phase II

Primary outcome measure

Overall cognitive function and impairment level measured using Korean Mini-Mental State Examination (K-MMSE) assessed before (baseline) and after the treatment (12 weeks)

Secondary outcome measures

Assessed before (baseline) and after the treatment (12 weeks):

1. Overall cognitive function and impairment level measured using Digit Forward Span (DFS), Digit Backward Span (DBS)
2. Overall depression level measured using Geriatric Depression Scale (GDS)

Overall study start date

15/09/2017

Completion date

30/10/2018

Eligibility

Key inclusion criteria

Current inclusion criteria as of 06/01/2020:

Stroke survivors with mild-to-moderate cognitive impairment (18 points or greater in K-MMSE) in their chronic stage (2 years or longer since their last onset)

Previous inclusion criteria:

Stroke survivors with mild cognitive function (18 points or greater in K-MMSE) in their chronic stage (1 year or longer since their last onset)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

50 in 2 clusters (1 experimental group, 1 passive control group), and 25 participants for each cluster

Key exclusion criteria

Visual neglect

Date of first enrolment

05/06/2018

Date of final enrolment

05/07/2018

Locations

Countries of recruitment

Korea, South

Study participating centre**Heeyeon Rehabilitation Hospital**

25 Woni-daero, Gyeongsangnam-do

Changwon

Korea, South

51420

Sponsor information

Organisation

University of Massachusetts Amherst

Sponsor details

Venture Way Center

100 Venture Way

Suite 201

Hadley

United States of America

01035

+1 (0)4135453428

ncswett@ora.umass.edu

Sponsor type

University/education

ROR

<https://ror.org/0072zz521>

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Publication and dissemination plan

The analyzed results will be submitted to a clinical journal by the end of March 2019.

Intention to publish date

31/03/2019

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available sharing the data was not part of the study plan, not approved by UMass IRB nor the study participants. Also, it was planned that the raw data would be removed completely once the analyzed results are published in academic journals. The data is currently stored in the secure online storage provided by UMass Amherst. The data is accessible only by researchers with valid authority.

IPD sharing plan summary

Not expected to be made available